Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Immix Biopharma Inc (IMMX)

Immix Biopharma Inc (IMMX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 59,967
  • Shares Outstanding, K 27,508
  • Annual Sales, $ 0 K
  • Annual Income, $ -15,430 K
  • EBIT $ -23 M
  • EBITDA $ -23 M
  • 60-Month Beta 0.28
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 3.41

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.17
  • Number of Estimates 1
  • High Estimate -0.17
  • Low Estimate -0.17
  • Prior Year -0.24
  • Growth Rate Est. (year over year) +29.17%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.60 +36.24%
on 11/27/24
2.71 -19.56%
on 12/06/24
+0.39 (+21.79%)
since 11/22/24
3-Month
1.26 +73.02%
on 10/04/24
2.71 -19.56%
on 12/06/24
+0.54 (+32.93%)
since 09/24/24
52-Week
1.26 +73.02%
on 10/04/24
7.46 -70.78%
on 12/26/23
-5.01 (-69.68%)
since 12/22/23

Most Recent Stories

More News
Immix Biopharma Reports Promising Initial Clinical Data for NXC-201 in Phase 1b/2 NEXICART-2 Trial for Relapsed/Refractory AL Amyloidosis

Four patients in the NEXICART-2 trial normalized disease markers after NXC-201 treatment, with promising initial responses reported.Quiver AI SummaryImmix Biopharma, Inc. announced positive initial clinical...

IMMX : 2.18 (unch)
Immix Biopharma Announces Positive U.S. Clinical Data From First Four Patients in NEXICART-2 U.S. Trial of sterically-optimized CAR-T NXC-201 in relapsed/refractory Light Chain (AL) Amyloidosis

IMMX : 2.18 (unch)
Immix Biopharma Announces Promising Clinical Results for CAR-T Therapy NXC-201 in Treating Relapsed/Refractory AL Amyloidosis

NXC-201 shows promising efficacy and safety in treating relapsed/refractory AL Amyloidosis, with a 75% complete response rate.Quiver AI SummaryImmix Biopharma, Inc. announced promising results from the...

IMMX : 2.18 (unch)
Journal of Clinical Oncology Publishes NXC-201 Positive Clinical Results in relapsed/refractory AL Amyloidosis

IMMX : 2.18 (unch)
Immix Biopharma Reports 75% Complete Response Rate and 31.5-Month Response Duration for CAR-T NXC-201 in Relapsed/Refractory AL Amyloidosis at ASH 2024

Immix Biopharma reports 75% complete response rate for CAR-T NXC-201 in relapsed/refractory AL Amyloidosis patients at ASH 2024.Quiver AI SummaryImmix Biopharma, Inc. reported promising results from its...

IMMX : 2.18 (unch)
Immix Biopharma Announces 75% Complete Response Rate (n=16); 31.5 months Best Response Duration (ongoing) for CAR-T NXC-201 in Relapsed/Refractory AL Amyloidosis Patients at ASH 2024

IMMX : 2.18 (unch)
Immix Biopharma to Host Conference Call on CAR-T NXC-201 Developments for AL Amyloidosis on December 10, 2024

Immix Biopharma will discuss CAR-T NXC-201 developments in AL Amyloidosis on a December 10 conference call.Quiver AI SummaryImmix Biopharma, Inc. will hold a conference call on December 10, 2024, at 4:30...

IMMX : 2.18 (unch)
Immix Biopharma to Host Conference Call for Investors, Analysts and Members of the Media

IMMX : 2.18 (unch)
Immix Biopharma Reports 75% Response Rate in Relapsed/Refractory AL Amyloidosis Patients for NXC-201 Ahead of ASH Presentation

NXC-201 shows 75% response rate in relapsed/refractory AL Amyloidosis, with data presented at ASH meeting in December 2024.Quiver AI SummaryImmix Biopharma, Inc. announced promising clinical trial results...

IMMX : 2.18 (unch)
Immix Biopharma Presents Positive NXC-201 Clinical Data at 66th American Society of Hematology (ASH) Annual Meeting in 16 Relapsed/Refractory AL Amyloidosis Patients

IMMX : 2.18 (unch)

Business Summary

Immix Biopharma Inc. is a biopharmaceutical company pioneering Tissue Specific Therapeutics (TM) targeting oncology and immuno-dysregulated diseases. Immix Biopharma Inc. is based in LOS ANGELES.

See More

Key Turning Points

3rd Resistance Point 2.48
2nd Resistance Point 2.38
1st Resistance Point 2.28
Last Price 2.18
1st Support Level 2.08
2nd Support Level 1.98
3rd Support Level 1.88

See More

52-Week High 7.46
Fibonacci 61.8% 5.09
Fibonacci 50% 4.36
Fibonacci 38.2% 3.63
Last Price 2.18
52-Week Low 1.26

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar